Discrete-wavelet-transform recursive inverse algorithm using second-order estimation of the autocorrelation matrix

The recursive-least-squares (RLS) algorithm was introduced as an alternative to LMS algorithm with enhanced performance. Computational complexity and instability in updating the autocolleltion matrix are some of the drawbacks of the RLS algorithm that were among the reasons for the intrduction of the second-order recursive inverse (RI) adaptive algorithm. The 2nd order RI adaptive algorithm suffered from low convergence rate in certain scenarios that required a relatively small initial step-size. In this paper, we propose a newsecond-order RI algorithm that projects the input signal to a new domain namely discrete-wavelet-transform (DWT) as pre step before performing the algorithm. This transformation overcomes the low convergence rate of the second-order RI algorithm by reducing the self-correlation of the input signal in the mentioned scenatios. Expeirments are conducted using the noise cancellation setting. The performance of the proposed algorithm is compared to those of the RI, original second-order RI and RLS algorithms in different Gaussian and impulsive noise environments. Simulations demonstrate the superiority of the proposed algorithm in terms of convergence rate comparedto those algorithms

Discrete wavelet transform-based RI adaptive algorithm for system identification

In this paper, we propose a new adaptive filtering algorithm for system identification. The algorithm is based on the recursive inverse (RI) adaptive algorithm which suffers from low convergence rates in some applications; i.e., the eigenvalue spread of the autocorrelation matrix is relatively high. The proposed algorithm applies discrete-wavelet transform (DWT) to the input signal which, in turn, helps to overcome the low convergence rate of the RI algorithm with relatively small step-size(s). Different scenarios has been investigated in different noise environments in system identification setting. Experiments demonstrate the advantages of the proposed DWT recursive inverse (DWT-RI) filter in terms of convergence rate and mean-square-error (MSE) compared to the RI, discrete cosine transform LMS (DCTLMS), discrete-wavelet transform LMS (DWT-LMS) and recursive-least-squares (RLS) algorithms under same conditions

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

Background: Tranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding. Methods: We did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124. Findings: Between July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98). Interpretation: We found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial

Mean-square deviation analysis of the zero-attracting variable step-size LMS algorithm

The well-known variable step-size least-mean-square (VSSLMS) algorithm provides faster convergence rate while maintaining lower mean-square error than the conventional LMS algorithm. The performance of the VSSLMS algorithm can be improved further in a channel estimation problem if the impulse response of the channel is sparse. Recently, a zero-attracting (ZA)-VSSLMS algorithm was proposed to exploit the sparsity of a channel. This was done by imposing an l(1) -norm penalty to the original cost function of the VSSLMS algorithm which utilizes the sparsity in the filter taps during the adaptation process. In this paper, we present the mean-square deviation (MSD) analysis of the ZA-VSSLMS algorithm. A steady-state MSD expression for the ZA-VSSLMS algorithm is derived. An upper bound of the zero-attractor controller (p) that provides the minimum MSD is also provided. Moreover, the effect of the noise distribution on the MSD performance is shown theoretically. It is shown that the theoretical and simulation results of the algorithm are in good agreement with a wide range of parameters, different channel, input signal, and noise types

Performance evaluation of logarithmic spiral search and selective mechanism based arithmetic optimizer for parameter extraction of different photovoltaic cell models.

The imperative shift towards renewable energy sources, driven by environmental concerns and climate change, has cast a spotlight on solar energy as a clean, abundant, and cost-effective solution. To harness its potential, accurate modeling of photovoltaic (PV) systems is crucial. However, this relies on estimating elusive parameters concealed within PV models. This study addresses these challenges through innovative parameter estimation by introducing the logarithmic spiral search and selective mechanism-based arithmetic optimization algorithm (Ls-AOA). Ls-AOA is an improved version of the arithmetic optimization algorithm (AOA). It combines logarithmic search behavior and a selective mechanism to improve exploration capabilities. This makes it easier to obtain accurate parameter extraction. The RTC France solar cell is employed as a benchmark case study in order to ensure consistency and impartiality. A standardized experimental framework integrates Ls-AOA into the parameter tuning process for three PV models: single-diode, double-diode, and three-diode models. The choice of RTC France solar cell underscores its significance in the field, providing a robust evaluation platform for Ls-AOA. Statistical and convergence analyses enable rigorous assessment. Ls-AOA consistently attains low RMSE values, indicating accurate current-voltage characteristic estimation. Smooth convergence behavior reinforces its efficacy. Comparing Ls-AOA to other methods strengthens its superiority in optimizing solar PV model parameters, showing that it has the potential to improve the use of solar energy

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

BackgroundTranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding.MethodsWe did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124.FindingsBetween July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98).InterpretationWe found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial.</div

SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study

Background: Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study aimed to inform their prioritization by modelling. Methods: The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18-49, 50-69, 70 or more years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty. Results: NNVs were more favourable in surgical patients than the general population. The most favourable NNVs were in patients aged 70 years or more needing cancer surgery (351; best case 196, worst case 816) or non-cancer surgery (733; best case 407, worst case 1664). Both exceeded the NNV in the general population (1840; best case 1196, worst case 3066). NNVs for surgical patients remained favourable at a range of SARS-CoV-2 incidence rates in sensitivity analysis modelling. Globally, prioritizing preoperative vaccination of patients needing elective surgery ahead of the general population could prevent an additional 58 687 (best case 115 007, worst case 20 177) COVID-19-related deaths in 1 year. Conclusion: As global roll out of SARS-CoV-2 vaccination proceeds, patients needing elective surgery should be prioritized ahead of the general population